Medicare is about to cover GLP-1 drugs for weight loss. Here’s what to know.
Medicare initiates a pilot program providing coverage for GLP-1 weight-loss medications beginning July 1, 2026.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Medicare is launching the GLP-1 Bridge Program, which allows eligible seniors to obtain specific weight-loss medications for $50 per month. This initiative marks the first time the federal program has covered these drugs for weight loss, specifically including Wegovy and Zepbound.
Reporting from outlets including CNBC, Reuters, and The New York Times emphasizes the eligibility criteria and the logistical requirements for patients. Coverage from Stat News and The American Bazaar highlights concerns regarding the long-term sustainability of the program and potential loopholes within the agreement established with manufacturers Novo Nordisk and Eli Lilly.
Observers are watching for the practical implementation of this temporary pilot program. Coverage does not yet specify the total duration of the initiative or the long-term plans for broader Medicare integration beyond this pilot phase.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (86% supported) Updated 139d ago.
Quick answers
What drugs are included in the Medicare coverage?
The program covers Wegovy and Zepbound, manufactured by Novo Nordisk and Eli Lilly.
What is the out-of-pocket cost for patients?
Eligible seniors can access these medications for $50 a month under the bridge program.
When does the coverage begin?
The pilot program is scheduled to begin on July 1, 2026.
Coverage (17)
- Pilot program to provide cheaper GLP-1 via Medicare stokes shortage fears The Guardian · 139d ago
- Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs CNBC · 139d ago
- Medicare is now covering some GLP-1 weight loss drugs for $50. Here’s what to know AP News · 140d ago
- GLP-1 drugs available for $50 a month under Medicare pilot Yahoo · 141d ago
- Medicare GLP-1 Bridge Program Will Pay for Novo, Lilly Drugs Barron's · 141d ago
- The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk statnews.com · 141d ago
- Medicare’s new GLP-1 Bridge Program is a good start, but not a long term solution The American Bazaar · 141d ago
- Medicare launches coverage of GLP-1 weight-loss drugs ConsumerAffairs · 141d ago
- Medicare will soon cover costs of weight-loss drugs. Here’s what you need to know AOL.com · 141d ago
- Medicare will start covering obesity drugs for the first time. Here's what patients should know CNBC · 141d ago
- Older Americans left out of costly GLP-1 craze expected to flock to new program Reuters · 141d ago
- What older adults need to know before taking a GLP-1 medication to lose weight CNN · 141d ago
- What Older Adults Should Know About GLP-1s as Medicare Coverage Expands The New York Times · 141d ago
- Eligible seniors can get GLP-1s for $50 a month for weight loss alone ABC News - Breaking News, Latest News and Videos · 141d ago
- Medicare (temporarily) covers GLP-1s starting tomorrow The Hill · 141d ago
- Medicare to cover GLP-1 drugs for weight loss for the first time starting July 1. Here's what to know. CBS News · 141d ago
- Medicare will help pay for weight-loss drugs Wegovy, Zepbound. What to know USA Today · 141d ago
Topics
Related trends
Here’s how much Medicare Part B premiums are rising in 2027
The Centers for Medicare & Medicaid Services announced that the standard Medicare Part B premium will increase by 3.2% for 2027.
GLP-1 poison calls surge in Georgia as experts warn about unapproved weight-loss drugs - WSB-TV
Georgia poison centers report a surge in calls linked to GLP-1 weight-loss drugs as experts flag risks from unapproved versions.
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.